- PR Newswire•4 days agoBenitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China
SYDNEY, Feb. 16, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that it will present pivotal data from the Company's hepatitis B virus (HBV) in vivo ...
- 24/7 Wall St.•17 days ago
Benitec Biopharma saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.
- PR Newswire•18 days ago
The results of this work will be presented by Dr David Suhy, Benitec's Chief Scientific Officer, at the Association for Research in Vision and Ophthalmology (ARVO)-Asia meeting being held in Brisbane on February 5th to February 8th, and the Translational Vision Summit (TVS), being held in conjunction. ARVO-Asia is a leading conference dedicated to eye and vision research in the Asia-Pacific region.
BLT.AX : Summary for BENITEC FPO - Yahoo Finance
Benitec Biopharma Limited (BLT.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.19 - 0.20|
|52 Week Range||0.09 - 0.27|
|PE Ratio (TTM)||-1.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|